These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 31883941)

  • 1. Clinical Outcomes of Patients With Histologic Variants of Urothelial Carcinoma Treated With Selective Tetramodal Bladder-preservation Therapy Incorporating Consolidative Partial Cystectomy.
    Kijima T; Tanaka H; Uehara S; Yoshida S; Yokoyama M; Ishioka J; Matsuoka Y; Saito K; Kihara K; Fujii Y
    Clin Genitourin Cancer; 2020 Aug; 18(4):268-273.e2. PubMed ID: 31883941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective tetramodal bladder-preservation therapy, incorporating induction chemoradiotherapy and consolidative partial cystectomy with pelvic lymph node dissection for muscle-invasive bladder cancer: oncological and functional outcomes of 107 patients.
    Kijima T; Tanaka H; Koga F; Masuda H; Yoshida S; Yokoyama M; Ishioka J; Matsuoka Y; Saito K; Kihara K; Fujii Y
    BJU Int; 2019 Aug; 124(2):242-250. PubMed ID: 30811784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Outcomes of Patients with Histologic Variants of Urothelial Cancer Treated with Trimodality Bladder-sparing Therapy.
    Krasnow RE; Drumm M; Roberts HJ; Niemierko A; Wu CL; Wu S; Zhang J; Heney NM; Wszolek MF; Blute ML; Feldman AS; Lee RJ; Zietman AL; Shipley WU; Efstathiou JA
    Eur Urol; 2017 Jul; 72(1):54-60. PubMed ID: 28040351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility and outcomes of selective tetramodal bladder-preservation therapy in elderly patients with muscle-invasive bladder cancer.
    Tanaka H; Fukushima H; Kijima T; Nakamura Y; Yajima S; Uehara S; Yoshida S; Yokoyama M; Ishioka J; Matsuoka Y; Saito K; Fujii Y
    Int J Urol; 2020 Mar; 27(3):236-243. PubMed ID: 31957164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High Ki-67 Expression Predicts Favorable Survival in Muscle-Invasive Bladder Cancer Patients Treated With Chemoradiation-Based Bladder-Sparing Protocol.
    Tanabe K; Yoshida S; Koga F; Inoue M; Kobayashi S; Ishioka J; Tamura T; Sugawara E; Saito K; Akashi T; Fujii Y; Kihara K
    Clin Genitourin Cancer; 2015 Aug; 13(4):e243-e251. PubMed ID: 25936588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal function outcome after selective bladder-preserving tetramodality therapy consisting of maximal transurethral resection, induction chemoradiotherapy and consolidative partial cystectomy in comparison with radical cystectomy for patients with muscle-invasive bladder cancer: a two-centre retrospective study.
    Fujiwara M; Yokoyama M; Toide M; Fujiwara R; Tanaka H; Oguchi T; Komai Y; Yoshida S; Matsuoka Y; Numao N; Yamamoto S; Fukui I; Yonese J; Fujii Y
    Jpn J Clin Oncol; 2023 Mar; 53(3):263-269. PubMed ID: 36524369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective bladder-sparing protocol consisting of induction low-dose chemoradiotherapy plus partial cystectomy with pelvic lymph node dissection against muscle-invasive bladder cancer: oncological outcomes of the initial 46 patients.
    Koga F; Kihara K; Yoshida S; Yokoyama M; Saito K; Masuda H; Fujii Y; Kawakami S
    BJU Int; 2012 Mar; 109(6):860-6. PubMed ID: 21854531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphovascular invasion, ureteral reimplantation and prior history of urothelial carcinoma are associated with poor prognosis after partial cystectomy for muscle-invasive bladder cancer with negative pelvic lymph nodes.
    Ma B; Li H; Zhang C; Yang K; Qiao B; Zhang Z; Xu Y
    Eur J Surg Oncol; 2013 Oct; 39(10):1150-6. PubMed ID: 23721764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathology-based risk stratification of muscle-invasive bladder cancer patients undergoing cystectomy for persistent disease after induction chemoradiotherapy in bladder-sparing approaches.
    Koga F; Fujii Y; Masuda H; Numao N; Yokoyama M; Ishioka J; Saito K; Kawakami S; Kihara K
    BJU Int; 2012 Sep; 110(6 Pt B):E203-8. PubMed ID: 22289431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of ERBB2 overexpression in therapeutic resistance and cancer-specific survival in muscle-invasive bladder cancer patients treated with chemoradiation-based selective bladder-sparing approach.
    Inoue M; Koga F; Yoshida S; Tamura T; Fujii Y; Ito E; Kihara K
    Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):303-11. PubMed ID: 25304790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant Chemotherapy-Guided Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: Results of a Pilot Phase II Study.
    Shi H; Zhang W; Bi X; Wang D; Xiao Z; Guan Y; Guan K; Tian J; Bai H; Hu L; Cao C; Jiang W; Hu Z; Zhang J; Chen Y; Zheng S; Feng X; Li C; Li Y; Ma J; Liu Y; Zhou A; Shou J
    Cancer Res Treat; 2021 Oct; 53(4):1156-1165. PubMed ID: 33592141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer.
    Jiang DM; Jiang H; Chung PWM; Zlotta AR; Fleshner NE; Bristow RG; Berlin A; Kulkarni GS; Alimohamed NS; Lo G; Sridhar SS
    Clin Genitourin Cancer; 2019 Feb; 17(1):38-45. PubMed ID: 30686350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder.
    Gakis G; Efstathiou J; Lerner SP; Cookson MS; Keegan KA; Guru KA; Shipley WU; Heidenreich A; Schoenberg MP; Sagaloswky AI; Soloway MS; Stenzl A;
    Eur Urol; 2013 Jan; 63(1):45-57. PubMed ID: 22917985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.
    Giacalone NJ; Shipley WU; Clayman RH; Niemierko A; Drumm M; Heney NM; Michaelson MD; Lee RJ; Saylor PJ; Wszolek MF; Feldman AS; Dahl DM; Zietman AL; Efstathiou JA
    Eur Urol; 2017 Jun; 71(6):952-960. PubMed ID: 28081860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bladder function preservation with brachytherapy, external beam radiation therapy, and limited surgery in bladder cancer patients: Long-term results [corrected].
    Aluwini S; van Rooij PH; Kirkels WJ; Boormans JL; Kolkman-Deurloo IK; Wijnmaalen A
    Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):611-7. PubMed ID: 24411629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radical transurethral resection alone, robotic or partial cystectomy, or extended lymphadenectomy: can we select patients with muscle invasion for less or more surgery?
    Cha EK; Donahue TF; Bochner BH
    Urol Clin North Am; 2015 May; 42(2):189-99, viii. PubMed ID: 25882561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of variant histological differentiation on extranodal extension and survival in node positive bladder cancer treated with radical cystectomy.
    Marks P; Gild P; Soave A; Janisch F; Minner S; Engel O; Vetterlein MW; Shariat SF; Sauter G; Dahlem R; Fisch M; Rink M
    Surg Oncol; 2019 Mar; 28():208-213. PubMed ID: 30851902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncological outcomes of concomitant carcinoma in situ at radical cystectomy in pure urothelial bladder cancer and in histological variants.
    Naspro R; La Croce G; Finati M; Roscigno M; Pellucchi F; Sodano M; Manica M; Gianatti A; Da Pozzo LF
    Urol Oncol; 2022 Feb; 40(2):61.e9-61.e19. PubMed ID: 34334293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tetramodal therapy with transurethral resection followed by chemoradiation in combination with hyperthermia for muscle-invasive bladder cancer: early results of a multicenter phase IIB study.
    Riesterer O; Ademaj A; Puric E; Eberle B; Beck M; Gomez S; Marder D; Oberacker E; Rogers S; Hälg RA; Kern T; Schwenne S; Stein J; Stutz E; Timm O; Zschaeck S; Weyland MS; Veltsista PD; Wyler S; Wust P; Scheidegger S; Bodis S; Ghadjar P
    Int J Hyperthermia; 2022; 39(1):1078-1087. PubMed ID: 35993234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladder-preservation therapy for muscle-invasive bladder cancer.
    Cahn DB; Handorf EA; Ghiraldi EM; Ristau BT; Geynisman DM; Churilla TM; Horwitz EM; Sobczak ML; Chen DYT; Viterbo R; Greenberg RE; Kutikov A; Uzzo RG; Smaldone MC
    Cancer; 2017 Nov; 123(22):4337-4345. PubMed ID: 28743162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.